CAROTID SINUS SYNDROME Evidence review. Introduction The hypersensitive carotid sinus syndrome (CSS) is defined as syncope or presyncope resulting from.

Slides:



Advertisements
Similar presentations
Research Study Designs
Advertisements

Syncope Wm. W. Barrington MD FACC Wm. W. Barrington MD FACC Associate Professor of Medicine University of Pittsburgh Medical Center PaACC Fellows in Training.
Patients with suspected syncope should be investigated by cardiologists Dr NR Stout.
Valsartan Antihypertensive Long-Term Use Evaluation Results
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
ISSUE 3 SYNCOPE ISSUE 3 International Study on Syncope of Uncertain Etiology 3 Pacemaker therapy for patients with neurally-mediated syncope and documented.
Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.
Can we prevent stent restenosis after coronary stent implantation
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2013.
Syncope AM Report 6/25/10 Nicole Wilde. Syncope  Cause Not Obvious Neurally Mediated (vasovagal) 58% Cardiac Disease (arrhythmias) 23% Neurologic or.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
Mode selection in pacemaker – Evidence review
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Overly concerning and falsely reassuring?? FRAMINGHAM RISK FACTORS IN THE ED.
Journal Club Ani Balmanoukian and Peter Benjamin November 9, 2006 Journal Club Ani Balmanoukian and Peter Benjamin November 9, 2006.
OVBIAGELE B, DIENER H-C, YUSUF S, ET AL., PROFESS INVESTIGATORS. LEVEL OF SYSTOLIC BLOOD PRESSURE WITHIN THE NORMAL RANGE AND RISK OF RECURRENT STROKE.
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2012.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
SWOONING AND VAPORS Syncope and near syncope. Syncope accounts for 3% ER visits Syncope/pre-syncope symptoms are due to a reduction in cerebral perfusion,
Cardiac stroke volume and sympathetic/parasympathetic measurements increase the sensitivity and specificity of HUTT in children and adolescents Mohammed.
The TRial Of Preventing HYpertension (TROPHY) TROPHY.
Devices and the older patient with syncope Michael Gammage, Reader in Cardiovascular Medicine MHRA Committee for Safety of Devices.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Vol 115, No. 3, pp , March 2007
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
Syncope diagnostic algorithm and management MUDr. Jakub Honěk Kardiologická klinika, 2.LF UK a FN Motol, Praha.
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial ONTARGET.
Adenosine testing in syncope Dr Steve W Parry Falls and Syncope Service Royal Victoria Infirmary and Institute for Ageing and Health, Newcastle University.
晕 厥 -Syncope 浙江大学医学院附属第二医院 心内科 项美香. Definition Syncope is a T-LOC (transient loss of conscious) due to transient global cerebral hypo-perfusion characterized.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
Neurocardiogenic syncope Evidence review. Introduction Neurocardiogenic (vasovagal) syncope is one of the most common cause of syncope. Occurs as a result.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
Efavirenz Use Not Associated With Depressive Episodes, According to Analysis of Randomized Clinical Trial Outcomes Slideset on: Journot V, Chene G, De.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Emergency Medicine Junior Teaching Programme Aberdeen Royal Infirmary Adult Syncope Evaluation in the Emergency Department Jamie Cooper Teaching 4 th March.
The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
Nephrology Journal Club The SPRINT Trial Parker Gregg
The SPRINT Research Group
HOPE: Heart Outcomes Prevention Evaluation study
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Systolic Blood Pressure Intervention Trial (SPRINT)
The Hypertension in the Very Elderly Trial (HYVET)
What is the most important etiology to rule out?
Section overview: Cardiometabolic risk reduction
Syncope diagnostic algorithm and management
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
Presentation transcript:

CAROTID SINUS SYNDROME Evidence review

Introduction The hypersensitive carotid sinus syndrome (CSS) is defined as syncope or presyncope resulting from an extreme reflex response to the carotid sinus stimulation. It affects 35–40 patients/million persons/year and is responsible for 1–20% of PP implantations and for 20–45% of unexplained falls or syncope in older patients. The CSS is more common in males (4:1) and in patients with diabetes and atherosclerosis Eltrafi A, King D et al; Postgrad Med J 2000 Davies AJ, Steen N et al; Age Ageing 2001

Questions to be answered…. How to identify a person with CSS? Role, reproducibility of CSM? Do we have to pace them? Pace mode selection? Recurrence of symptoms after pacing?

Age distribution CSH is an age-related phenomenon – Rarely diagnosed in patients with syncope < 50 years – Prevalence increases with advancing age Unexplained syncope—is screening for carotid sinus hypersensitivity indicated in all patients aged > 40 years? J Neurol Neurosurg Psychiatry 2006;77:1267–1270

Carotid sinus massage A ventricular pause lasting >3 s and/or a fall in systolic BP of >50 mmHg defines carotid sinus hypersensitivity (CSH). When associated with spontaneous syncope, CSH defines CSS.

Europace subjects with CICSH and unexplained or recurrent falls.(61% female, mean age 71·8 years, median 2 falls in the previous year) completed 1 yr F/U and had CSM performed on 4 occasions (twice before randomization, at 6 months and 1 yr). Results CICSH was demonstrated on 82% of occasions, 75% on right CSM and 77% whilst the subject was supine. Before randomization, and at 6 months and 1 year, 91%, 67%, and 70% of subjects had reproducible CICSH respectively. Half had CICSH on all 4 occasions. Only 17% had a consistent response on the same side in the same position

272 participants(>65 yrs) underwent supine and upright carotid sinus massage with continuous heart rate and blood pressure monitoring. RESULTS: CSH was present in 107 individuals (39%); 24% had asystole of ≥3 seconds during CSM; and 16% had symptoms (including syncope) with CSM. Age (OR, 1.05; 95% CI, ) and male sex (OR, 1.71; 95% CI, ) were the only predictors of carotid sinus hypersensitivity. In 80 previously asymptomatic individuals, CSH was present in 28 (35%) and accompanied by symptoms in 10. CONCLUSION: CSH is common in older persons, even those with no history of syncope, dizziness, or falls. The finding of a hypersensitive response should not necessarily preclude further investigation for other causes of syncope.

Cardioinhibitory carotid sinus hypersensitivity predicts an asystolic mechanism of spontaneous neurally mediated syncope. Europace 2007, Maggi, Menozzi etal Correlated CSH with that observed during a spontaneous syncopal relapse by means of ILR. 18 CSM+ vs. 36 CSM- pts, suspected recurrent neurally mediated recurrent syncope. Asystole >3 s was observed at the time of the spontaneous syncope in 16 (89%) of CSH patients and in 18 (50%) of the control group (P = 0.007). Sinus arrest- 72 vs. 28%, P = CSH patients with asystole received DDI. Syncope burden decreased from 1.68 to 0.04 episodes per yr per person. (98% relative risk reduction).

BENEFIT OF PACING

A randomized treatment/nontreatment prospective study. 60 pts affected by carotid sinus syndrome. They were randomly assigned to 2 groups: 28 patients to nonpacing group and 32 to VVI (n = 18) or DDD (n = 14) pacing group. Syncope recurred in 16 pts (57%) of the nonpacing group (mean follow-up 36 +/- 10 months) and in only 3 (9%) of the pacing group (mean follow-up 34 +/- 10 months) (p = ). 19 (68%) in the nonpacing group needed a secondary pacemaker implant because of the severity of symptoms. Reproducibility of carotid sinus reflex was tested after 15 +/- 8 months in 54 patients; an abnormal response to carotid sinus massage persisted in all 54.

Europace 2011 To assess the outcome of patients with CSS treated with pacemaker and to determine predictors of symptom recurrence. A retrospective analysis of 138 patients in whom pacemaker was implanted for CSS. Mean age was 69±10.7 yrs an 75.4% were men. Mean follow-up period was 4.9±4.4 yrs. 21 (15.2%) pts presented mixed CSS and 117 (84.8%) CICSS. After PPI, 115 (83.3%) pts had no further symptoms, 8 (5.8%) presented minor symptoms and in 15 (10.9%) the symptoms remained unchanged. Among pts with symptoms recurrence, 8 (38.1%) had mixed CSS and 15 (12.8%) cardioinhibitory CSS. Mixed CSS was the only independent predictor of symptoms recurrence in total population {hazard ratio (HR) 2.84 [95% CI 1.20–6.71]; P=

JACC 2001 The aim of the study was to determine whether cardiac pacing reduces falls in older adults with CICSH.

RESULTS The primary outcome was the number of falls during one year of follow-up. Falls (without LOC) were reduced by two-thirds: controls reported 669 falls (mean 9.3; range 0 to 89) and paced patients 216 falls (mean 4.1; range 0 to 29). Odds ratio 0.42; 95% CI: Syncopes were also reduced but there were much fewer syncopal events than falls—28 episodes in paced patients and 47 in controls. Injurious events were reduced by 70% (202 vs 61).

Heart 2010 To assess the efficacy of dual-chamber pacing in older patients with CICSH and unexplained falls. A multicentre, double blind, randomised controlled trial. Patients aged >50 years, with two unexplained falls and/or one syncopal event in the previous 12 months for which no other cause is evident apart from CICSH. 141 pts -randomized to rate responsive pacemaker or implantable loop recorder. The primary outcome- the number falls after implantation.

Results 141 patients were recruited from 22 centres. Mean age was 78 years and mean follow-up 24 months. The overall relative risk of falling after device implantation compared with before was 0.23 (0.15 to 0.32). No significant reduction in falls was seen between paced and loop recorder groups (RR=0.79; 95% CI 0.41 to 1.50).

These results question the use of pacing in CICSH. The study was underpowered Patient characteristics differed from those in Safepace-1 (participants were physically and cognitively frailer)

 Patients: Consecutive subjects aged over 55 years with CSH with ≥ 3 unexplained falls in the 6 months preceding enrollment.  Intervention: Dual-chamber permanent pacing with rate drop response programming. The pacemaker was switched on (DDD/RDR) or off (ODO (placebo)) for 6 months, then crossed over to the alternate mode for a further 6 months.  The primary outcome: number of falls in paced and non-paced modes.  Results: 25 of 34 subjects (mean years (SD 9.0), 27 (79%) female) recruited completed the study. Pacing intervention had no effect on number of falls (4.04 (9.54) in DDD/RDR mode, 3.48 (7.22) in ODO; relative risk of falling in ODO mode 0.82, 95% CI 0.62 to 1.10).  Conclusion: Permanent pacing intervention had no effect on fall rates in older patients with CSH.

Role of pacing in CSS The role of pacemaker in hypersensitive carotid sinus syndrome Europace (2011) 13, 572–575 Permanent pacemaker is an effective treatment

MODE OF PACING

Is DDD Superior to VVI Pacing in Mixed Carotid Sinus Syndrome? An Acute and Medium-Term Study Pacing and Clinical Electrophysiology 1988;brignole et al 23 pts affected by symptomatic mixed carotid sinus syndrome- received a DDD pacemaker and entered a 2 month two period single-blind, randomized, cross- over study on DVI/DDD versus VVI mode. During the DVI/DDD period, no syncope occurred in any pts, minor symptoms persisted in 11 (48%) of them. During VVI period syncopes recurred in 3 pts, symptoms requiring the withdrawal of VVI pacing and premature DVI/DDD reprogramming in 8 pts, minor symptoms in 17 (74%). A comparison between 14 pts who preferred DVI/DDD period (Group A), and the remaining 9 who noted no preference between DVI/DDD and VVI period (Group B). Group A patients had a greater pacemaker effect (-34 ± 16 mmHg vs -16 ± 14 mmHg) and a higher prevalence of symptomatic pacemaker effect (50% vs 0%)of ventriculo-atrial conduction (78% vs 44%) and of orthostatic hypotension (50% vs 11%) DVI/DDD pacing is more effective than VVI in 61% of patients.

A study comparing VVI and DDI pacing in elderly patients with carotid sinus syndrome Shona J McIntosh et al; Heart 1997 Prospective double blind randomised cross over study. 30 consecutive pts >60 years with CSS referred for cardiac pacing. Patients underwent dual chamber PPI and randomised to 2 three month periods of VVI and DDI pacing. Main outcome measures-Responses to cardiovascular tests (vasodepression during CSM, pacemaker effect, postural BP measurements and response to head up tilt) and symptoms.

Results 11 pts were unable to tolerate VVI pacing and had to be withdrawn early from this limb of the study (group A). 14 pts had no preference (group B). No patient preferred VVI. Elderly patients with carotid sinus syndrome are likely to develop symptomatic hypotension following single chamber ventricular pacing.

RECURRENCE OF SYMPTOMS AFTER PACING?

All subjects who had had pacemaker implantation for cardio-inhibitory CSH were followed up. 2 groups: Pts- >1 episode of syncope and controls- without syncope or 1 syncope only. They were clinically evaluated and a new CSM done to record the response. Each subject had 2 CSMs, the first at enrolment and pacemaker implantation and the last at reevaluation. The mean followup period 72 months.

Syncope recurrence was seen in 35% of subject 28% had a vasodepressive effective SCM and 10% had symptoms during the maneuver. The pts selected and treated for cardio-inhibition changed their patterns at CSM (a new vasodepressive response) and by the appearance of OH, leaded to symptom recurrence. Dysautonomia may occur in these pts (association between CSH & OH). Indicates that CSH is a generalized autonomic disorder.